Cannabis in Managed Alcohol Programs: Clinical and Program Considerations
Last Updated: February 2026 | Reading Time: 5 minutes
Managed Alcohol Programs occupy a specific and evidence-supported niche in harm reduction: they serve people with severe alcohol use disorder and housing instability who are not reached by abstinence-based treatment and for whom unmanaged drinking carries acute and ongoing risk. The question of whether adding cannabis substitution to MAP services produces meaningful harm reduction outcomes now has a quantitative Canadian answer, published in peer-reviewed literature in 2026.
This article reviews what the evidence shows about cannabis substitution in MAP settings and what it means for clinical and program decision-making.
The Quantitative Benchmark: What the Ottawa Findings Establish
The most rigorous published evidence comes from Goulet-Stock, Hacksel, Scandiuzzi, Boyd, Pauly & Stockwell (2026), published open-access in the International Journal of Drug Policy (147: 105083). The Ottawa MAP study followed N=35 participants over two years using hierarchical mixed-effects modelling to assess the relationship between cannabis use and alcohol consumption.
The final model found a statistically significant between-person substitution effect. Each additional 0.4-gram pre-rolled joint consumed, containing approximately 15.2 standard THC units or 76 mg THC, was associated with an estimated 2.43 fewer mean daily standard drinks. For a population consuming 10–15 standard drinks per day, this represents a clinically meaningful reduction magnitude per unit of cannabis provided.
Two additional findings are relevant for clinical and program interpretation. First, within-person daily cannabis fluctuations were not significantly associated with same-day changes in alcohol use — the substitution effect operated through stable individual patterns established over time, not acute day-to-day trade-offs. Second, alcohol use declined over time as an independent trend, separate from and in addition to the cannabis substitution effect. Cannabis substitution and time-in-program effects appear to compound rather than compete.
Pre-Implementation Readiness: The Feasibility Evidence
Before running the pilots, CMAPS conducted a multi-site feasibility assessment across six Canadian MAPs (Pauly, Brown, Chow, Wettlaufer, Graham, Urbanoski et al., 2021, Harm Reduction Journal, 18: 65). For program directors evaluating whether their site could implement cannabis substitution, this study functions as a readiness checklist.
The findings: 84% of MAP participants expressed willingness to participate in a cannabis substitution program. Over 63% of enrolled clients were already using cannabis to substitute for alcohol at baseline — meaning the majority of the potential participant population was already practising informal substitution without a regulated supply. The study identified three implementation requirements: peer support infrastructure, a sustainable regulated supply, and stable funding. Programs that have peer workers already embedded in service delivery, access to a licensed cannabis producer, and a funding mechanism have the structural prerequisites the evidence identifies as necessary.
The Withdrawal Dimension
One of the most clinically significant findings from the Vancouver component of CMAPS, with High Hopes Research Society as program operator, involves withdrawal. “Sick cups” are the MAP term for alcohol doses dispensed specifically to address withdrawal symptoms. The Vancouver analysis found a direct, moderately strong, and statistically significant association between grams of High Hopes cannabis dispensed and number of sick cups dispensed per day (coeff=-0.278, p=0.0076). As cannabis became more accessible at the program site, instances of acute withdrawal — the most medically urgent alcohol harm in this population — became less frequent or less acute.
This finding is currently in peer review at Drug & Alcohol Review and should not be cited until accepted. It is noted here to indicate the direction of the evidence for program planning purposes.
What the Research Does Not Establish
The Ottawa findings are from a specific MAP population — people with severe AUD and housing instability — using a specific supply model (pre-rolled joints at 16–22% THC, distributed by peer researchers with a one-joint-per-alcohol-dose protocol). The 2.43 drinks reduction per additional joint is an effect size from that population and that model. Extrapolating it to other settings, supply configurations, or patient populations goes beyond what the evidence supports.
The feasibility finding that 63% of clients were already substituting at baseline also means cannabis substitution is not uniformly adopted by MAP participants. Approximately 37% were not doing so, and the pilot data show a range of individual outcomes. Program design should account for individual variation rather than treating substitution as a uniform effect.
Supply and Licensing Considerations for Program Operators
Cannabis substitution within a MAP requires a licensed Canadian producer with the appropriate federal license category. Health Canada’s producer without possession license model enables drop-shipping directly to program sites or participants without requiring physical cannabis custody at an intermediate point. For MAP operators evaluating supply logistics, this license type eliminates the need for on-site storage and inventory management by the program itself.
High Hopes Research Society, the organization under which Flora Initiative operates, holds this license type and has direct experience operating cannabis substitution within a MAP setting as documented in the CMAPS research program.
This article summarizes published peer-reviewed research for informational purposes. It is intended for program administrators and healthcare professionals and does not constitute clinical guidelines.
References
- Goulet-Stock, Hacksel, Scandiuzzi, Boyd, Pauly & Stockwell (2026). International Journal of Drug Policy, 147: 105083. DOI: 10.1016/j.drugpo.2025.105083
- Pauly, Brown, Chow, Wettlaufer, Graham, Urbanoski et al. (2021). Harm Reduction Journal, 18: 65. DOI: 10.1186/s12954-021-00512-5